Related Experiment Video
Updated: Aug 4, 2026
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
Basal ganglia lesions after MPTP administration in rhesus monkeys
M E Emborg1, J Moirano, K T Schafernak
1Wisconsin National Primate Research Center, University of Wisconsin-Madison, 53715, USA. emborg@primate.wisc.edu
Abstract:
In monkeys, intracarotid infusion of a single low dose of MPTP reliably induces a hemiparkinsonian syndrome that is stable over time. This model has been widely used to assess novel anti-parkinsonian therapies. Here, we report the exceptional finding of severe necrotic lesions that were observed in the basal ganglia (but not in the substantia nigra) of monkeys that received a single intracarotid injection of MPTP followed by gene therapy treatments. Although extensive unilateral dopaminergic nigrostriatal loss was found in all the animals, partial behavioral recovery was observed in the subjects that presented pallidal necrotic lesions. This report discusses possible causes and effects of the necrotic lesions and their locations and the value of the intracarotid MPTP model. Testing novel therapies in monkey models has become an essential step before clinical trials. These results indicate that evaluation of any treatment should consider possible confounding factors that may affect the results.
Insights
A study on monkeys found unexpected necrotic lesions in the basal ganglia after MPTP infusion and gene therapy. These lesions, while not in the substantia nigra, correlated with partial behavioral recovery in Parkinsonian models.
Area of Science:
- Neuroscience
- Primate Models
- Parkinson's Disease Research
Background:
- The intracarotid MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) infusion in monkeys reliably creates a stable hemiparkinsonian syndrome.
- This primate model is crucial for evaluating new anti-Parkinsonian therapies before human clinical trials.
Purpose of the Study:
- To investigate the unexpected development of severe necrotic lesions in the basal ganglia of monkeys treated with MPTP and gene therapy.
- To analyze the impact of these lesions on dopaminergic loss and behavioral recovery in a Parkinson's disease model.
Main Methods:
- Monkeys received a single intracarotid injection of MPTP.
- Subsequent gene therapy treatments were administered.
- Neuropathological examination focused on the basal ganglia and substantia nigra.
- Behavioral assessments were conducted to evaluate motor function.
Main Results:
- Severe necrotic lesions were observed in the basal ganglia, specifically excluding the substantia nigra, in monkeys receiving MPTP and gene therapy.
- All animals exhibited extensive unilateral dopaminergic nigrostriatal loss.
- Partial behavioral recovery was noted in subjects with pallidal necrotic lesions.
Conclusions:
- The study highlights the potential for confounding factors, such as unexpected necrotic lesions, in MPTP-induced Parkinsonism models.
- Understanding the cause and effect of these lesions is vital for interpreting therapeutic outcomes in preclinical primate studies.
- Results emphasize the need to carefully evaluate treatments considering potential iatrogenic effects in animal models.
